Akebia's vadadustat meets in Phase II dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) reported top-line data from a double-blind, Japanese Phase II study in 60 patients with anemia associated with dialysis-dependent chronic kidney disease (CKD) showing that 150, 300 and 600 mg doses of oral vadadustat each met the primary endpoint

Read the full 426 word article

User Sign In